[go: up one dir, main page]

AR078846A1 - Composicion para el tratamiento de la enfermedad de alzheimer - Google Patents

Composicion para el tratamiento de la enfermedad de alzheimer

Info

Publication number
AR078846A1
AR078846A1 ARP100104015A ARP100104015A AR078846A1 AR 078846 A1 AR078846 A1 AR 078846A1 AR P100104015 A ARP100104015 A AR P100104015A AR P100104015 A ARP100104015 A AR P100104015A AR 078846 A1 AR078846 A1 AR 078846A1
Authority
AR
Argentina
Prior art keywords
disease
alzheimer
treatment
methods
composition
Prior art date
Application number
ARP100104015A
Other languages
English (en)
Inventor
Serguei Nabirochkin
Daniel Cohen
Ilya Chumakov
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of AR078846A1 publication Critical patent/AR078846A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Composiciones y métodos para el tratamiento de la enfermedad de Alzheimer y los trastornos relacionados. Más específicamente, se describen terapias de combinacion para la enfermedad de Alzheimer y los trastornos relacionados. En particular, se describen compuestos que, solos o en combinacion/es pueden modular efectivamente la funcion de sinapsis y/o angiogénesis y/o la respuesta al estrés celular. También se describen métodos para producir una droga o una combinacion de drogas para tratar la enfermedad de Alzheimer y métodos para tratar la enfermedad de Alzheimer o los trastornos relacionados. Reivindicacion 1: Una composicion para su uso en el tratamiento de la enfermedad de Alzheimer (AD) o un trastorno relacionado, caracterizada porque comprende al menos ácido aminocaproico o levosimendán, o sales o prodrogas o derivados o formulaciones de liberacion sostenida de los mismos.
ARP100104015A 2009-11-03 2010-10-29 Composicion para el tratamiento de la enfermedad de alzheimer AR078846A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09306048A EP2322163A1 (en) 2009-11-03 2009-11-03 New therapeutics approaches for treating alzheimer disease

Publications (1)

Publication Number Publication Date
AR078846A1 true AR078846A1 (es) 2011-12-07

Family

ID=41693027

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104015A AR078846A1 (es) 2009-11-03 2010-10-29 Composicion para el tratamiento de la enfermedad de alzheimer

Country Status (12)

Country Link
US (1) US8809302B2 (es)
EP (4) EP2322163A1 (es)
JP (2) JP5977172B2 (es)
CN (2) CN107261144A (es)
AR (1) AR078846A1 (es)
BR (1) BR112012010470A2 (es)
CA (2) CA2779070C (es)
EA (1) EA024465B1 (es)
ES (1) ES2800311T3 (es)
IL (1) IL219412A (es)
MX (1) MX2012005131A (es)
WO (1) WO2011054759A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
CA2722295C (en) * 2008-04-29 2019-01-15 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP3604302A1 (en) 2010-05-17 2020-02-05 Forum Pharmaceuticals Inc. Preparation of crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
DK2560631T3 (da) 2011-03-01 2014-02-10 Pharnext Baclofen- og acamprosat-baseret af neurologiske forstyrrelser
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
CN102861017A (zh) * 2011-07-08 2013-01-09 辽宁省计划生育科学研究院 一种化合物在防治老年痴呆的应用
AU2013224959B2 (en) * 2012-03-01 2017-12-07 Pharnext New compositions for treating amyotrophic lateral sclerosis
RS56175B1 (sr) * 2012-03-01 2017-11-30 Pharnext Nove kompozicije za lečenje amiotrofične lateralne skleroze
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit
EP2705841A1 (en) * 2012-09-05 2014-03-12 Pharnext Combinations of nootropic agents for treating cognitive dysfunctions
CA2889446C (en) 2012-10-25 2021-05-11 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
TR201815059T4 (tr) 2013-06-05 2018-11-21 Pharnext Birleşik Apı' ye Yönelik Kararlı Oral Çözeltiler
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
KR20150056443A (ko) * 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
WO2015072700A1 (en) * 2013-11-15 2015-05-21 Hanmi Pharm. Co., Ltd. Composite formulation comprising tadalafil and amlodipine
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2015217796B2 (en) 2014-02-11 2020-04-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
WO2016030345A1 (en) * 2014-08-26 2016-03-03 Fundación Para La Investigación Médica Aplicada Products for the treatment and prevention of neurological disorders coursing with a cognition deficit or impairment, and of neurodegenerative diseases
AU2015353853B2 (en) * 2014-11-25 2020-10-15 President And Fellows Of Harvard College Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
ES2930628T3 (es) 2015-02-25 2022-12-20 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la memoria
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US10520493B2 (en) * 2015-03-13 2019-12-31 National Cheng Kung University Method for assessment of neural function by establishing analysis module
CN104888199A (zh) * 2015-04-21 2015-09-09 徐志强 降钙素在制造治疗老年痴呆症新药物的用途
EP3347002B1 (en) * 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
JP6879560B2 (ja) * 2015-12-29 2021-06-02 国立大学法人京都大学 アルツハイマー病の予防及び／又は治療剤
WO2017201364A1 (en) * 2016-05-20 2017-11-23 Vanda Pharmaceuticals Inc. Method for improving or enhancing cognition
AU2017275652B2 (en) 2016-06-03 2023-02-16 Levo Therapeutics, Inc. Methods of treating Prader-Willi syndrome
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
KR101910153B1 (ko) * 2016-11-04 2018-10-19 한국과학기술연구원 타우 관련 질환의 예방 또는 치료용 레보시멘단 화합물
AU2018258970B2 (en) 2017-04-24 2021-07-15 Pharnext Idalopirdine-based combinatorial therapies of Alzheimer's disease
CA3064006C (en) 2017-05-19 2025-09-16 Biscayne Neurotherapeutics, Inc. Modified-Release Pharmaceutical Compositions of Huperzine and Their Methods of Use
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
US9962384B1 (en) * 2017-09-07 2018-05-08 Korea Institute Of Science And Technology Levosimendan compound for preventing or treating tau-related diseases
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
JP7037814B2 (ja) * 2018-03-28 2022-03-17 国立大学法人山口大学 ホルボールエステルを有効成分とする軸索の伸展剤
JP2019182845A (ja) * 2018-04-02 2019-10-24 学校法人藤田学園 キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤
KR102317080B1 (ko) * 2018-05-09 2021-10-25 한국과학기술연구원 타우 관련 질환의 예방 또는 치료용 조성물
WO2019216589A1 (ko) * 2018-05-09 2019-11-14 한국과학기술연구원 타우 관련 질환의 예방 또는 치료용 조성물
CN113038944A (zh) 2018-07-02 2021-06-25 通用医疗公司 色甘酸钠和α-乳糖的粉末化制剂
CN108707204B (zh) * 2018-07-04 2020-09-15 吉林大学 过氧化氢响应型靶向载药纳米材料及制备方法
EP4541419A3 (en) 2018-11-19 2025-05-07 Supernus Pharmaceuticals, Inc. Use of higher doses of modified release huperzine formulations
AU2019397436A1 (en) 2018-12-10 2021-07-22 The General Hospital Corporation Cromolyn esters and uses thereof
WO2021011421A1 (en) * 2019-07-12 2021-01-21 University Of South Florida Compositions and methods for treating alzheimers disease
WO2021037027A1 (en) * 2019-08-29 2021-03-04 The Hong Kong University Of Science And Technology Genetic variants for diagnosis of alzheimer's disease
ES2821599A1 (es) * 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
CN110656170A (zh) * 2019-11-08 2020-01-07 新乡医学院 一种用于阿尔茨海默病诊断的试剂、诊断产品、治疗组合物，候选药物筛选方法及应用
WO2021142312A1 (en) * 2020-01-10 2021-07-15 The Board Of Regents Of The University Of Texas Methods and compositions related to heparinoids
IL297023A (en) 2020-04-06 2022-12-01 Massachusetts Gen Hospital Methods for treating inflammatory conditions caused by the corona virus
CN115955968B (zh) * 2020-06-19 2025-07-15 韩国科学技术研究院 包含通过接头连接的两个或更多个芳基或杂芳基的新型碳腙酰二腈化合物及其用途
AR122677A1 (es) * 2020-06-19 2022-09-28 Korea Inst Sci & Tech Nuevos compuestos de dicianuro de heterociclil-carbonohidrazonoílo fusionado y su uso
EP4196595B1 (en) * 2020-08-11 2025-03-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Method for the treatment of wwox associated diseases
CN111983241B (zh) * 2020-09-04 2022-05-20 四川大学华西医院 诊断脑卒中认知障碍的蛋白标志物以及模型的训练方法
JP7578275B2 (ja) 2020-12-14 2024-11-06 日本メナード化粧品株式会社 Ｂｍｐｒ２産生促進剤
CN114832116B (zh) * 2022-05-19 2024-01-26 沈阳药科大学 基于小胶质细胞表型调节和脑内铁清除的ros响应型纳米载体及其制备方法与应用
CN115354048B (zh) * 2022-06-08 2024-02-02 暨南大学 阿尔茨海默病动物模型的构建方法、用途和Aβ42重组表达载体
CN115851946B (zh) * 2022-11-24 2023-09-01 中山大学孙逸仙纪念医院 CaMK I作为治疗靶点在制备胰腺癌治疗药物中的应用
CN117568466B (zh) * 2023-11-20 2024-07-09 南方医科大学南方医院 动脉重塑标志物及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06502184A (ja) * 1991-02-22 1994-03-10 シャピロ，ハワード　ケイ． 神経性疾病の症候や原因上関係のある症候の治療のための薬用化合物の使用
EP1262182A3 (en) * 1991-11-26 2003-02-26 Sepracor Inc. Methods and compositions for treating hypertension, angina and other disorders using optically pure(-) amlodipine
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US6573251B2 (en) * 1994-03-30 2003-06-03 Denis Barritault Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
JPH101439A (ja) * 1996-06-11 1998-01-06 Mochida Pharmaceut Co Ltd 神経変性疾患治療剤
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
EP1406660B1 (en) * 2001-07-19 2007-06-06 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor
EP1485104A1 (en) * 2002-03-18 2004-12-15 Pharmacia Corporation Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US7547715B2 (en) * 2002-10-10 2009-06-16 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production accelerator
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
FI20040674A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
US20080025962A1 (en) * 2004-11-30 2008-01-31 Angesmg,Inc. Remedy for Alzheimer's Disease
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
CN101309682A (zh) * 2005-10-21 2008-11-19 脑细胞股份有限公司 通过pde抑制调节神经发生
EP2314289A1 (en) * 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
JP2009532663A (ja) * 2006-02-16 2009-09-10 レリアント ファーマスーティカルズ インコーポレイテッド ω−３脂肪酸を用いた、痴呆、脳血管性痴呆、パーキンソン痴呆、アルツハイマー病及び／又は軽度認知障害の治療により利益を得ると考えられる患者を同定し、治療する方法
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
CA2654033A1 (en) * 2006-05-31 2007-12-06 Dnavec Corporation Therapeutic agent for alzheimer's disease
WO2008006070A2 (en) * 2006-07-06 2008-01-10 Roskamp Research Llc Compounds and combinations thereof for inhibiting beta-amyloid production and methods of use thereof
WO2008009639A2 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors
AU2008253977B2 (en) * 2007-05-22 2013-08-22 Juntendo University A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease
JP5736098B2 (ja) * 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
US20100137442A2 (en) 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
LT2282778T (lt) * 2008-04-29 2017-06-26 Pharnext Nauji terapijos būdai, gydant alzheimerio ligą ir susijusius sutrikimus per angiogenezės moduliaciją
CA2722295C (en) * 2008-04-29 2019-01-15 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
CN102065897B (zh) * 2008-04-29 2013-11-13 法奈科斯公司 基于磺胺异噁唑的组合物用于制备治疗阿茨海默病的药物的应用
EP2377865B1 (en) 2008-11-27 2014-12-17 National University Corporation Kagawa University Cyclobutyl purine derivative, angiogenesis promoting agent, lumenization promoting agent, neurocyte growth promoting agent, and drug
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
DK2560631T3 (da) 2011-03-01 2014-02-10 Pharnext Baclofen- og acamprosat-baseret af neurologiske forstyrrelser

Also Published As

Publication number Publication date
JP6062995B2 (ja) 2017-01-18
IL219412A (en) 2017-05-29
JP5977172B2 (ja) 2016-08-24
EA024465B1 (ru) 2016-09-30
MX2012005131A (es) 2012-05-29
CA2779070A1 (en) 2011-05-12
EP3650021A1 (en) 2020-05-13
EA201200686A1 (ru) 2013-05-30
US20120270836A1 (en) 2012-10-25
EP2322163A1 (en) 2011-05-18
JP2015157841A (ja) 2015-09-03
CA3065614A1 (en) 2011-05-12
EP3797767A1 (en) 2021-03-31
BR112012010470A2 (pt) 2016-03-08
ES2800311T3 (es) 2020-12-29
WO2011054759A1 (en) 2011-05-12
EP2496226B1 (en) 2020-03-04
CA2779070C (en) 2020-02-25
CN107261144A (zh) 2017-10-20
US8809302B2 (en) 2014-08-19
JP2013510114A (ja) 2013-03-21
EP2496226A1 (en) 2012-09-12
CN102834095A (zh) 2012-12-19
IL219412A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
AR078846A1 (es) Composicion para el tratamiento de la enfermedad de alzheimer
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
MX2010005931A (es) Profarmacos de tetrahidrocanabinol, composiciones que comprenden profarmacos de tetrahidrocanabinol y metodos para utilizar los mismos.
CY1118956T1 (el) Νεες θεραπευτικες προσεγγισεις για τη θεραπευτικη αντιμετωπιση της νοσου alzheimer και των συγγενων διαταραχων μεσω διαμορφωσης της αγγειογενεσης
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
PA8836101A1 (es) Inhibidores alfa7 nicotínicos del receptor de acetilcolina
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
CL2008002542A1 (es) Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
CL2009000498A1 (es) Compuestos derivados de benzo [f][1,7]naftiridin sustituidos, moduladores de receptor toll; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedad infecciosa, inflamatoria, dermatologica, respiratoria o inmune.
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CR9667A (es) Derivados de benzamida y usos relacionados con los mismos
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
UY30460A1 (es) Compuestos terapéuticos
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
CR11600A (es) Derivados de indazol

Legal Events

Date Code Title Description
FB Suspension of granting procedure